Premium
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
Author(s) -
Tepasse PhilRobin,
Hafezi Wali,
Lutz Mathias,
Kühn Joachim,
Wilms Christian,
Wiewrodt Rainer,
Sackarnd Jan,
Keller Martin,
Schmidt Hartmut H.,
Vollenberg Richard
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16896
Subject(s) - rituximab , medicine , immunosuppression , pneumonia , disease , covid-19 , immunology , intensive care medicine , infectious disease (medical specialty) , antibody
Summary SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after rituximab therapy.